Gavin M. Marx
185 Fox Valley Road
Wahroonga, NSW 2076, Australia
Wahroonga, NSW 2076, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 60 publications
Enzalutamide Monotherapy for the Treatment of Prostate Cancer with High-Risk Biochemical Recurrence: EMBARK Secondary End Points: Erratum.
Journal: The Journal of urology
Published: July 09, 2026
Eight-year outcomes of testosterone suppression plus enzalutamide or a non-steroidal anti-androgen for metastatic, hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304).
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 01, 2026
Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary End Points.
Journal: The Journal of urology
Published: December 05, 2025
WOMBAT (ANZUP 2201): A Phase 2, Single-arm Study of Bipolar Androgen Therapy in Patients with Nonmetastatic Castration-resistant Prostate Cancer with Prostate-specific Antigen Progression on Darolutamide.
Journal: European urology oncology
Published: November 19, 2025
WOMBAT (ANZUP 2201): A Phase 2, Single-arm Study of Bipolar Androgen Therapy in Patients with Nonmetastatic Castration-resistant Prostate Cancer with Prostate-specific Antigen Progression on Darolutamide.
Journal: European urology oncology
Published: November 19, 2025
Radiographic Progression Without Prostate-specific Antigen Progression in Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Analysis of the ENZAMET Trial (ANZUP 1304).
Journal: European urology oncology
Published: November 10, 2025
Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette-Guérin-naïve Non-muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301).
Journal: European urology
Published: October 02, 2025
A protocol for pre-treatment testing for antibodies to galactose-alpha-1,3-galactose to mitigate the risk of cetuximab hypersensitivity reactions - a retrospective cohort review.
Journal: Cancer treatment and research communications
Published: April 10, 2025
Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304).
Journal: Future oncology (London, England)
Published: January 17, 2025
Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 16, 2024
Validity of Patient-Reported Outcome Measures in Evaluating Nerve Damage Following Chemotherapy.
Journal: JAMA network open
Published: August 09, 2024
Single-fraction or multi-fraction stereotactic ablative body radiotherapy followed by atezolizumab in advanced triple-negative breast cancer: a randomized phase II trial.
Journal: Nature communications
Published: July 20, 2024
Last Updated: 09/26/2026